|
Press Releases
October 6, 2008
Provectus Lead Investigator Professor John F. Thompson Gives Update on PV-10 Phase 2 Study
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT
http://www.pvct.com)
announced that that the interim safety analysis on the first 20 subjects in its phase 2 clinical trial for
the treatment of metastatic melanoma has been completed. PV-10 injection was well tolerated by this group, with
an adverse event profile similar to that observed in phase 1. In addition, long-term survival data for subjects
participating in the phase 1 trial were presented.
Read the complete article here.
October 2, 2008
Provectus Lead Investigator Professor John F. Thompson Presents at "Perspectives in Melanoma XII" Conference
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT
http://www.pvct.com)
announced that the lead investigator for its Phase 2 melanoma study, Professor John F Thompson, MD, today presented clinical data on PV-10 at the "Perspectives in Melanoma XII" meeting at The Hague, The Netherlands. Professor Thompson's presentation was entitled "PV-10 Chemoablation of cutaneous and subcutaneous metastatic melanoma."
Read the complete article here.
September 29, 2008
Provectus Receives $1.1 Million from Warrant Conversions
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT
http://www.pvct.com)
announced today that it has received approximately $1.1 million from the early conversion of some of its outstanding warrants.
The Company now has approximately $5 million cash on hand to fund operations.
Read the complete article here.
September 9, 2008
Provectus Pharmaceuticals Inc. Will Present at the Wall Street Analyst Forum 19th Annual Analyst Conference
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT
http://www.pvct.com)
today announced that Chairman and CEO, Craig Dees, Ph.D., will present at The Wall Street Analyst Forum 19th Annual Analyst Conference on Wednesday, September 10 at 11:50 a.m. Eastern time.
This conference will be held at The University Club in New York. It will also be webcast at
http://wsw.com/webcast/wsaf7/pvct.ob
Read the complete article here.
August 26, 2008
Professor John F. Thompson to Present at Perspectives in Melanoma XII, Thursday October 2, 2008
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT
http://www.pvct.com)
announced today that the Lead Investigator for its phase 2 melanoma study, Professor John F. Thompson, MD,
will present clinical data on PV-10 at the Perspectives in Melanoma XII meeting at The Hague, The Netherlands.
Read the complete article here.
July 21, 2008
Provectus Pharmaceuticals to Hold Business Update Conference Call at 4:15 pm EDT, on Tuesday, July 22, 2008
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT
http://www.pvct.com),
will hold a conference call to update the market on its business on Tuesday, July 22, 2008 at 4:15 pm Eastern Daylight Time.
Read the complete article here.
|
